AI Insight
Healthcare's 66/100 average AI exposure masks sharp divergence: AI-native biotech like Insilico Medicine (82) and Tempus AI (78) dwarf traditional pharma giants Pfizer (48) and Moderna (46). Only two companies face HIGH AI threat despite sector-wide transformation, suggesting incumbent drugmakers lag in AI integration.